Phobia, Social Clinical Trial
Official title:
Investigating the Effects of Cannabidiol on Social Anxiety Disorder
The purpose of this study is to test whether a single-dose of Epidiolex (cannabidiol) is associated with reduced psychological, physiological, and neuroimaging measures of anxiety in people diagnosed with social anxiety disorder (SAD).
Using a randomized, double-blind, placebo-controlled, parallel-group study design, this scientific investigation will examine the effect of 3 milliliters (mL) of Epidiolex (100mg cannabidiol/mL) on behavioral, physiological, and neuroimaging measures of anxiety in subjects diagnosed with SAD. The study will enroll 50 subjects with SAD who will be randomized in a double-blind manner to receive either Epidiolex or placebo before experiencing the Trier Social Stress Test (TSST), the gold-standard for ethically inducing stress in a controlled laboratory setting. Following the TSST, neuroimaging measures of emotional processing and self-referential processing will be acquired using functional magnetic resonance imaging (fMRI). This study will be conducted primarily at Massachusetts Institute of Technology with research and clinical support from Massachusetts General Hospital. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02590770 -
Gaze Contingent Feedback in Social Anxiety Disorder
|
N/A | |
| Completed |
NCT00751465 -
Dysfunctional Attention Processes in Fear of Blushing: Specificity and Changeability
|
N/A | |
| Completed |
NCT03630783 -
Combined CBM For Social Anxiety in Turkey
|
N/A | |
| Terminated |
NCT00182533 -
Sertraline in Generalized Social Phobia With Co-Occurring Anxiety and Mood Disorders
|
Phase 4 | |
| Completed |
NCT01470469 -
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
|
Phase 2 | |
| Completed |
NCT01557894 -
Internet Treatment for Social Phobia in Romania
|
N/A |